

CLIENT: VITAL TRANSFORMATION


Corporate ID, Website and various materials

Logo



VitalTransformation

The impact of health technology made simple




Fully responsive website



Display stand

CLIENT: VITAL TRANSFORMATION

Event website and pack



Fully responsive website




Event Pack



PowerPoint Template

CLIENT: VITAL TRANSFORMATION

Fully Responsive Websites



CLIENT: VITAL TRANSFORMATION

Event Programmes

BETTER SCIENCE BETTER HEALTH

Advanced Therapies – Opportunities and Challenges

A EUROPEAN PERSPECTIVE TO ACCELERATE ADVANCED THERAPIES

14TH NOVEMBER 2017, LONDON

Brought to you by:

VitalTransformation

Supported by:

BETTER SCIENCE BETTER HEALTH

Advanced Therapies – Opportunities and Challenges

#BSBH17

BETTER SCIENCE BETTER HEALTH

ADVANCED THERAPIES – OPPORTUNITIES AND CHALLENGES

BETTER SCIENCE BETTER HEALTH

Advanced Therapies – Opportunities and Challenges

SPEAKERS

Richard Barker, OBE
FOUNDING DIRECTOR, CASMI

Richard is a leader in rethinking the medical innovation process. As head of the UK pharmaceutical industry association (ABPI) he formed the Athenaeum Group, with leaders of the major UK and European regulators, to develop a more streamlined and flexible model for drug development. He subsequently founded the Oxford-UCL academic group CASMI (Centre for the Advancement of Sustainable Medical Innovation) which has worked with IMI, the UK Government and the Wellcome Trust to advance adaptive pathways of development, and other strategies to overcome the gaps in translation in biomedical innovation.

He is also chair of the Health Innovation Network of South London, the charity International Health Partners and the company Image Analysis; he is a member of the board of Celgene.

His OUP book '2030 The Future of Medicine – Avoiding a Medical Meltdown' has recently been followed by a second 'Bioscience – Lost in Translation?' on the subject of CASMI's work.

Steve Bates, OBE
CHIEF EXECUTIVE OFFICER, BIOINDUSTRY ASSOCIATION (BIA)

Since his appointment as Chief Executive Officer of the Biotechnology Association in 2012, Steve Bates has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors.

Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK's leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK's Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry & Translation Committee.

Beyond the UK Steve is a member of EuropaBio's Board and its National Association Council and is a founder member and Vice-Chair of the International Council of Biotech Associations.

An expert and regular commentator on the sector in the media and at industry-leading conferences, Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair's government) for over 15 years.

In the 2016 New Year's Honours List Steve was awarded an OBE for his services to Innovation.

Eduardo Bravo
FOUNDER AND CHIEF EXECUTIVE OFFICER, TIGENIX
PRESIDENT, EBE

Prior to joining Tigenix in 2005, Eduardo held several senior management and commercial positions at Sanofi-Aventis and SmithKline Beecham, lastly as Vice President for Latin America for Sanofi-Aventis. He holds a degree in Business Administration and an MBA from INSEAD. Eduardo is President of the EBE (European Biopharmaceutical Enterprises) Board of Directors and member of the Executive Committee of ARM (Alliance for Regenerative Medicine).

Ian Campbell
DIRECTOR FOR HEALTH AND LIFE SCIENCES, INNOVATE UK

Dr Ian Campbell is an experienced executive in the life sciences. Ian joined Innovate UK in October 2016 as Director for Health and Life Sciences. Prior to that, he most recently served as Chief Executive of Arguer Diagnostics, a company developing and commercialising immunoassay tests for cancers of the urogenital tract. He was also Chief Executive of Imperial College spin-out company Molecular Vision, developing a disposable, quantitative point-of-care diagnostic platform, before the company was acquired by Abingdon Health in 2012. Ian has also served as Commercial Director with Bespak Europe. Ian has a strong scientific background, gaining his PhD at the University of Glasgow.

Barbara Freischem
EXECUTIVE DIRECTOR, EUROPEAN BIOPHARMACEUTICAL ENTERPRISES (EBE)

Barbara Freischem is Executive Director of the European Biopharmaceutical Enterprises (EBE), since July 2015. EBE is a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA), representing biopharmaceutical companies of all sizes. Barbara has worked at national, European and international level. Starting out on the side of regulatory authorities, her career spans working in the pharmaceutical industry, industry associations as well as in an international intergovernmental organisation. Barbara, a German national, holds a degree in veterinary medicine from the Free University of Berlin.

BETTER SCIENCE BETTER HEALTH

ADVANCED THERAPIES – OPPORTUNITIES AND CHALLENGES

#BSBH17

CLIENT: VITAL TRANSFORMATION


Event Programmes

28TH-29TH JUNE 2017 TALLINN, ESTONIA

EMIF: DIGITAL CITIZEN DIGITAL PATIENT

Supporters:

Brought to you by: VitalTransformation



“There still remain challenges, but I do think in EMIF-AD, EMIF-MET and the EMIF platform, we have now got models for sharing medical data,” says Nigel Hughes, of Janssen Pharmaceutica, EMIF platform co-lead. “It is evident no one data source represents a universal truth; you need the strength of numbers. By opening the way of pooling data, EMIF has made it possible to demonstrate the value of sharing.”

Digital citizen, digital patient: EMIF makes it as good to give as to receive

An Interview with Nigel Hughes, Scientific Director, Quantitative Sciences at Janssen Research and Development

By removing barriers to data exchange, EMIF has provided potent demonstrations of the power of pooling resources in Alzheimer's disease and metabolic disorders. These exemplars are incentivising data sharing, says Nigel Hughes of Janssen Pharmaceutica, EMIF platform co-lead.

Data sharing is easier said than done. There are different types of data, varying data quality, different source populations, cohorts and registries with which to contend – to say nothing of the need to overcome the tug of ownership or the time-consuming nature of making your data available to others.

The European Medical Information Framework (EMIF) programme aimed to remove this friction by putting in place interoperability standards, a governance compact and compiling a catalogue of relevant data sources from electronic health records to cohorts), forming a nexus for the re-use of health data.

“There still remain challenges, but I do think in EMIF-AD, EMIF-MET and the EMIF platform, we have now got models for sharing medical data,” says Nigel Hughes. “It is evident no one data source represents a universal truth; you need the strength of numbers. By opening the way of pooling data, EMIF has made it possible to demonstrate the value of sharing.”

EMIF-AD and EMIF-MET are intended to be pathfinders of the ‘how to’ of pooling medical data and – by using shared data to discover early biomarkers of disease – as demonstrators of the added value that comes from sharing.

“The idea is to be able to pick up on extreme phenotypes – that can be very informative – in contrast to the mass of subjects in the middle,” Hughes says.

Without EMIF, it would not have been possible to assemble such large data sets in such a short time. Most of the cohorts are relatively small and tend to take an in-depth look at a few specific variables, rather than taking in the broad sweep of potential disease pathology.

“There may only be a few hundred or so subjects in each cohort. Given this, the ability to unify these data sets is very powerful,” says Hughes.

Pooling cohorts can also provide the basis for carrying out different kinds of studies that individual cohorts could not support. For example, it may be possible to track the natural history of a disease against specific biomarkers or to look at what medication, or not, subjects were taking and how that influences the trajectory of a disease.

New knowledge from historical data

“EMIF-AD and EMIF-MET have shown how important existing data sources are and the potential for learning from what we have now,” Hughes says. While it can be a challenge to work with disparate and historical data, the rewards are there, he believes. “However, it is critical to have the analytical tools to interpret the data and that can be a concern. The quality must be maintained.”

In addition, EMIF has created a space for collaboration between academics, clinicians and pharma, which is promoting the translation of publicly-funded research and, in turn, engendering trust.

For Hughes, this is one of the most valuable aspects of the programme. “Some days, I am working more with collaborators from academia or from other companies than with my own Janssen colleagues. That is not an everyday occurrence for most people and is one of the successes of EMIF.”

With the EMIF programme due to finish at the end of the year, attention has turned to preserving its value for the future. The hope is to secure an informal extension until June 2018, both to complete all work packages and work on preserving the legacy.

Since EMIF was conceived five years ago, much has changed in terms of the technology and the perception of real world evidence, Hughes noted.

“It has all exploded. We are evaluating how EMIF can be linked into these changes and how EMIF feeds into the next wave of IMI projects.”

AGENDA

June 29th 2017
Hilton, Tallinn, Estonia

8:30 - 9:30	Registration & Coffee
9:00 - 9:10	Welcome Bart Vannieuwenhuyse Quantitative Sciences, Janssen Pharmaceutica & Coordinator EMIF
9:10 - 10:40	Opening Keynote Session: Supporting a Data Driven Patient Journey in Europe – How Can Member States Help Drive Results? Ain Aviksoo Deputy Secretary General on eServices and Innovation, Ministry of Social Affairs, Estonia Pierre Meulien Executive Director, IMI Bart Vannieuwenhuyse Quantitative Sciences, Janssen Pharmaceutica & Coordinator EMIF Terje Peetso Head of eHealth and Ageing Policy Sector, DG CONNECT, European Commission
10:40 - 11:10	Coffee Break
11:10 - 12:40	Patient Driven Data Generation – What Are the Evolving Trends and Opportunities? Elin Haf Davies CEO and Founder, Aparito, UK Kille Tärnov Connected Health Cluster Manager, Tallinn Science Park Tehnopol, Estonia Bettina Ryll Founder, Melanoma Patient Network Europe Dainius Pavalkis Professor, Lithuanian University of Health Sciences, former Minister of Education and Science, Lithuania and member of RISE HL (Research and innovation strategic expert high level group), European Commission
12:40 - 13:25	Networking Lunch
13:25 - 14:40	Incentivising the Sharing of Stakeholder Health Data – What works? Nigel Hughes Scientific Director, Quantitative Sciences, Janssen Research and Development Lembit Rõgo Secretary-General, Council for International Organizations of Medical Sciences (CIOMS) Pieter Jelle Visser Clinical Epidemiologist, Maastricht University Alison Bourke Scientific Director, QuintilesIMS
14:40 - 15:00	Coffee Break
15:00 - 16:15	Harnessing Health Data for Managing Patient Benefit Risk – What new processes are needed? Nicola Bedington Secretary General, European Patients' Forum Lili Milani Senior Scientist, Estonian Genome Center, Tartu University, Estonia Johan van der Lei Professor Doctor, Erasmus MC Amsterdam, The Netherlands Wim Goettsch Director, EUnetHTA J43 Directorate/Zorginstituut, The Netherlands
16:15 - 17:30	Networking Cocktail

Join the conversation on #EMIF17 or @IMI_EMIF